Merck's Covid-19 Pill Does Not Cut Hospitalisation, Death Rates in Many Vaccinated Adults: Study

Merck & Co Inc's Covid-19 antiviral molnupiravir speeds up recovery but does not reduce the hospitalisation or death rate in higher-risk vaccinated adults, detailed data from a large study showed on Thursday (Dec 22).

The drug, which prevents the virus from replicating, generated nearly US$5 billion (S$6.76 billion) in sales for the US drugmaker in the first three quarters of 2022.

Preliminary data from the study, carried out in the winter of 2021-2022 when the Omicron variant was dominant, was unveiled in October. As a result, doctors are already considering limiting molnupiravir's use, for instance, in Australia.

For the two Covid drugs, which are under an Emergency Use Authorization, the drug companies say that the drugs are new and so not all side-effects are known, and they don't show the list of known side effects - you have to ask your doctor for those. Wonder if your doctor will tell you...

The brand name is Lagevrio.

~~~~~~~~~~~~~~~~

What Are Side Effects of Lagevrio?

Lagevrio may cause serious side effects including:

hives,
difficulty breathing,
swelling of your face, lips, tongue, or throat,
dizziness

Side effects of Lagevrio include:

diarrhea,
nausea, and
dizziness.

Get medical help right away, if you have any of the symptoms listed above.

Lagevrio is still being studied, so it is possible all of the risks are not known at this time.

Seek medical care or call 911 at once if you have the following serious side effects:
Serious eye symptoms such as sudden vision loss, blurred vision,tunnel vision,eye painor swelling, or seeing halos around lights;
Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheartedness, or passing out;

Severe headache,confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

https://www.rxlist.com/lagevrio-side-effects-drug-center.htm

Merck’s Covid-19 Pill Does Not Cut Hospitalisation, Death Rates in Many Vaccinated Adults: Study
AsiaOne ^ | DECEMBER 22, 2022

3 minute read December 22, 20223:37 PM PSTLast Updated 20 hours ago

Merck’s COVID pill does not cut hospitalisation, death rates in many vaccinated adults - study
By Natalie Grover

LONDON, Dec 22 (Reuters) - Merck & Co Inc’s (MRK.N) COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalisation or death rate in higher-risk vaccinated adults, detailed data from a large study showed on Thursday.

Reporting by Natalie Grover in London; Editing by Richard Chang

my two cents.

basically the highly mutative nature of corona viridae and use of leaky jabs has made the virus mutate so fast that monoclonal is not generally effective as it has to be tailored to a specific variant.

if you can get a monoclonal treatment *specific* to the variant you are infected with, say in the first 5 days, it works pretty well.

however, i wouldn’t choose monoclonal because of the immoral way these treatments are developed. the use of humanized mice, and cell lines from aborted fetal tissue, for instance. i don’t blame anyone else for using the treatment if they are informed. it was reported Trump used a treatment successfully early on targeted for the initial ccp virus.

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.